Value in assessing new vaccines

Italian Journal of Public Health

Volumn 6, Issue 3, 2009, Pages 202-204

  la Torre, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449584979     PISSN: 17237815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. WHO. Immunization against diseases of public health importance. Available from: http://www.who.int/mediacentre/factsheets/fs288/en/index.html [Accessed July 16, 2009]
2. Kieny MP, Excler JL, Girard M. Research and development of new vaccines against infectious diseases. Am J Public Health. 2004;94(11):1931-5.
3. WHO. UNICEF. GIVS. Global Immunization Vision and Strategy 2006-2015. Available from: http://www.who.int/vaccines- documents/DocsPDF05/GIVS_Final_EN.pdf [Accessed July 16, 2009].
4. La Torre G, Chiaradia G, de Waure C, Mannocci A, Capri S, Bruno S, Cicchetti A, Bucci R, Bamfi F, Patarnello F, Marocco A, Ricciardi W, and HTA Collaborative Group. Health technology assessment and vaccine: new needs and opportunities? Ital J Public Health 2007; 4(1): 81-8.
5. World Bank. Investing in health: The World Development Report 1993. Washington, DC: World Bank, 1993.
6. Munira SL, Fritzen SA. What influences government adoption of vaccines in developing countries? A policy process analysis. Social Science & Medicine 2007; 65: 1751-64.
7. Lee K. Health Economic Assessment of Pneumococcal Vaccine and the Challenges Facing the Cost-effective use of Health Care Resources in HK. School of Farmacy Hong Kong 2008. Available from: http://www.pharmacy.cuhk.edu.hk/presentation/kenneth.pdf [Accessed September 21, 2009].
8. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccinationprogrammes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26(3):191-215.
9. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313(7052):275-83.
10. La Torre G, Chiaradia G, de Waure C, Nicolotti N, Monteduro A, Ricciardi W. REPORT HTA DEL VACCINO QUADRIVALENTE ANTI-HPV GARDASIL. Ital J Public Health 2009; 6(2 S2): 1-66.
11. Moran N, Shickle D, Richardson E. European citizens' opinions on immunisation. Vaccine 2008; 26: 411-8.
12. La Torre G, de Waure C, Chiaradia G, Mannocci A, Specchia ML, Nicolotti N, Ricciardi W. The future of best investing in vaccines: the Health Technology Assessment approach. Vaccine 2008;26(13):1609-10 (b).
13. La Torre G, Chiaradia G, Mannocci A, de Waure C, Ricciardi W, Capri S, Bamfi F, Bianchi C, Lapinet-Vera J, Marocco A, Patarnello F, Recchia G. Health technology assessment della vaccinazione anti-HPV. Ital J Public Health 2007; 4(2 S): 1-60.
14. La Torre G, Chiaradia G, de Waure C, Nicolotti N, Monteduro A, Ricciardi W. Report HTA del vaccino quadrivalente anti-HPV Gardasil. Ital J Public Health 2009; 2 (S2):1-68.
15. WHO. The Tallinn Charter: Health Systems for Health and Wealth, 2008b, available at http://www.euro.who.int/document/E91438.pdf [Accessed September 21, 2009].